Axa S.A. Jounce Therapeutics, Inc. Transaction History

Axa S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$6.01 - $8.54 $90,751 - $128,953	-15,100 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $147,177 - $199,548	-20,700 Reduced 57.82%	15,100 $126,000
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $78,624 - $136,188	15,600 Added 77.23%	35,800 $266,000
Q2 2021 Aug 13, 2021	SELL	$6.58 - $10.66 $313,208 - $507,416	-47,600 Reduced 70.21%	20,200 $137,000
Q1 2021 May 14, 2021	BUY	$6.73 - $13.87 $96,912 - $199,728	14,400 Added 26.97%	67,800 $696,000
Q3 2020 Nov 13, 2020	SELL	$4.58 - $10.95 $92,516 - $221,190	-20,200 Reduced 27.45%	53,400 $436,000
Q4 2019 Feb 18, 2020	BUY	$2.81 - $9.21 $206,816 - $677,856	73,600 New	73,600 $643,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.